Non-coding RNAs: the "dark Matter" of Cardiovascular Pathophysiology

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2013 Oct 12

PMID 24113581

Citations 28

Authors

Claudio Iaconetti

Clarice Gareri

Alberto Polimeni

Ciro Indolfi

Affiliations

Soon will be listed here.

Abstract

Large-scale analyses of mammalian transcriptomes have identified a significant number of different RNA molecules that are not translated into protein. In fact, the use of new sequencing technologies has identified that most of the genome is transcribed, producing a heterogeneous population of RNAs which do not encode for proteins (ncRNAs). Emerging data suggest that these transcripts influence the development of cardiovascular disease. The best characterized non-coding RNA family is represented by short highly conserved RNA molecules, termed microRNAs (miRNAs), which mediate a process of mRNA silencing through transcript degradation or translational repression. These microRNAs (miRNAs) are expressed in cardiovascular tissues and play key roles in many cardiovascular pathologies, such as coronary artery disease (CAD) and heart failure (HF). Potential links between other ncRNAs, like long non-coding RNA, and cardiovascular disease are intriguing but the functions of these transcripts are largely unknown. Thus, the functional characterization of ncRNAs is essential to improve the overall understanding of cellular processes involved in cardiovascular diseases in order to define new therapeutic strategies. This review outlines the current knowledge of the different ncRNA classes and summarizes their role in cardiovascular development and disease.

Citing Articles

The Role of Circulating Biomarkers in Patients with Coronary Microvascular Disease.

Quarta R, Martino G, Romano L, Lopes G, Greco F, Spaccarotella C Biomolecules. 2025; 15(2).

PMID: 40001480 PMC: 11853534. DOI: 10.3390/biom15020177.

Importance of long non-coding RNAs in the pathogenesis, diagnosis, and treatment of myocardial infarction.

Zolfaghari Dehkharghani M, Mousavi S, Kianifard N, Fazlzadeh A, Parsa H, Tavakoli Pirzaman A Int J Cardiol Heart Vasc. 2024; 55:101529.

PMID: 39498345 PMC: 11532444. DOI: 10.1016/j.ijcha.2024.101529.

A 2-decade bibliometric analysis of epigenetics of cardiovascular disease: from past to present.

Mao Y, Zhao K, Chen N, Fu Q, Zhou Y, Kong C Clin Epigenetics. 2023; 15(1):184.

PMID: 38007493 PMC: 10676610. DOI: 10.1186/s13148-023-01603-9.

Clinical relevance of circulating non-coding RNAs in metabolic diseases: Emphasis on obesity, diabetes, cardiovascular diseases and metabolic syndrome.

Dandare A, Khan M, Naeem A, Liaquat A Genes Dis. 2023; 10(6):2393-2413.

PMID: 37554181 PMC: 10404886. DOI: 10.1016/j.gendis.2022.05.022.

Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias.

Gareri C, Polimeni A, Giordano S, Tamme L, Curcio A, Indolfi C J Clin Med. 2022; 11(13).

PMID: 35807171 PMC: 9267663. DOI: 10.3390/jcm11133884.

References

Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M . A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011; 147(2):358-69. PMC: 3234495. DOI: 10.1016/j.cell.2011.09.028. View

Albinsson S, Suarez Y, Skoura A, Offermanns S, Miano J, Sessa W . MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function. Arterioscler Thromb Vasc Biol. 2010; 30(6):1118-26. PMC: 2880481. DOI: 10.1161/ATVBAHA.109.200873. View

Wang S, Aurora A, Johnson B, Qi X, McAnally J, Hill J . The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008; 15(2):261-71. PMC: 2685763. DOI: 10.1016/j.devcel.2008.07.002. View

Ule J, Jensen K, Mele A, Darnell R . CLIP: a method for identifying protein-RNA interaction sites in living cells. Methods. 2005; 37(4):376-86. DOI: 10.1016/j.ymeth.2005.07.018. View

Alexander R, Fang G, Rozowsky J, Snyder M, Gerstein M . Annotating non-coding regions of the genome. Nat Rev Genet. 2010; 11(8):559-71. DOI: 10.1038/nrg2814. View

Quintavalle M, Elia L, Condorelli G, Courtneidge S . MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J Cell Biol. 2010; 189(1):13-22. PMC: 2854384. DOI: 10.1083/jcb.200912096. View

Curcio A, Torella D, Indolfi C . Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J. 2011; 75(6):1287-96. DOI: 10.1253/circj.cj-11-0366. View

Van Rooij E, Quiat D, Johnson B, Sutherland L, Qi X, Richardson J . A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell. 2009; 17(5):662-73. PMC: 2796371. DOI: 10.1016/j.devcel.2009.10.013. View

Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li P . miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci U S A. 2009; 106(29):12103-8. PMC: 2715539. DOI: 10.1073/pnas.0811371106. View

10.

Alexander M, Owens G . Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol. 2011; 74:13-40. DOI: 10.1146/annurev-physiol-012110-142315. View

11.

Yap K, Li S, Munoz-Cabello A, Raguz S, Zeng L, Mujtaba S . Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010; 38(5):662-74. PMC: 2886305. DOI: 10.1016/j.molcel.2010.03.021. View

12.

Ganesan J, Ramanujam D, Sassi Y, Ahles A, Jentzsch C, Werfel S . MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation. 2013; 127(21):2097-106. DOI: 10.1161/CIRCULATIONAHA.112.000882. View

13.

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M . MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456(7224):980-4. DOI: 10.1038/nature07511. View

14.

Davis-Dusenbery B, Chan M, Reno K, Weisman A, Layne M, Lagna G . down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J Biol Chem. 2011; 286(32):28097-110. PMC: 3151055. DOI: 10.1074/jbc.M111.236950. View

15.

Ten Dijke P, Arthur H . Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007; 8(11):857-69. DOI: 10.1038/nrm2262. View

16.

Zheng B, Han M, Wen J . Role of Krüppel-like factor 4 in phenotypic switching and proliferation of vascular smooth muscle cells. IUBMB Life. 2010; 62(2):132-9. DOI: 10.1002/iub.298. View

17.

Holdt L, Teupser D . Recent studies of the human chromosome 9p21 locus, which is associated with atherosclerosis in human populations. Arterioscler Thromb Vasc Biol. 2012; 32(2):196-206. DOI: 10.1161/ATVBAHA.111.232678. View

18.

da Costa Martins P, Salic K, Gladka M, Armand A, Leptidis S, Azzouzi H . MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol. 2010; 12(12):1220-7. DOI: 10.1038/ncb2126. View

19.

Chen H, Untiveros G, McKee L, Perez J, Li J, Antin P . Micro-RNA-195 and -451 regulate the LKB1/AMPK signaling axis by targeting MO25. PLoS One. 2012; 7(7):e41574. PMC: 3402395. DOI: 10.1371/journal.pone.0041574. View

20.

Luther H . Role of endogenous antisense RNA in cardiac gene regulation. J Mol Med (Berl). 2004; 83(1):26-32. DOI: 10.1007/s00109-004-0613-5. View